540sek
-4,9 %
Date:2025-04-03Time:10:57:13Latest report:Q4-2024List:First NorthTicker:ONCOZ
Market Cap:63 msekEnterprise Value:59 msekNet Sales:- msekEarnings:-8,69 msekEmployees:0ISIN:SE0015504097

Ratios

10-year key figure history for OncoZenge turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for OncoZenge with index and moving average MA50 and MA200.

Stockprice:5,40
MA50:5,91
MA200:5,77
Price/MA200:-6,4 %
RSI (14):42,7
Price/MA50:-8,6 %

Description

OncoZenge AB is a pharmaceutical company that is developing a new treatment for effective pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. In phase 2 patient studies, the company's product candidate BupiZenge displayed pain relief compared with standard therapy. It focuses on implementing a phase development program as a basis for regulatory approvals and product launches.

Pharmaceuticals